Billerica, Mass.-based Insulet, which makes the Omnipod insulin management system for treating diabetes, said it closed a private placement of $345 million principal amount in convertible senior notes, due 2021, with an annual interest rate of 1.25%.
The notes will bear a conversion rate of 17.1 shares of common stock per $1,000, approximately $58.37 per share of common stock, the company said. Net proceeds from the round were approximately $334 million, according to an SEC filing.
Approximately $154 million from the sale will be used to repurchase $134 million in outstanding 2% convertible senior notes due 2019. Funds will also be used to support manufacturing and supply chain operations, Insulet said.
Insulet originally unveiled plans for the round last week, saying it planned to fund a new, automated U.S. plant in part with the proceeds from the expected $250 million debt offering.
A day earlier, the company revealed a 5-year deal with ATS Automation Tooling Systems to construct an automated manufacturing assembly line.
The $35 million contract calls for ATS to design, build and install manufacturing equipment developed according to technical specifications provided by Insulet. In addition to helping cover that tab, the debt offering is earmarked for “general corporate purposes,” including various refinancing moves and the settlement of its 2.0% convertible senior notes due in 2019. Investments in supply chain operations could also be in the offing, the company said.
Earlier this week Insulet launched a clinical trial of an artificial pancreas system based on its flagship Omnipod insulin management device for treating Type I diabetes.
The Omnipod Horizon automated glucose control system will link the Omnipod with continuous glucose monitoring technology from DXCM, Billerica, Mass.-based Insulet said. The 20-patient trial is designed to evaluate a “model predictive control” algorithm it acquired from a University of California-Santa Barbara spinout earlier this year.